Fellowship Program

Since its inception in 2005, the Sickle Cell Awareness Group of Ontario (SCAGO) has been supporting research in order to improve the health outcomes and quality of life of all people with sickle cell disease in Ontario. To ensure more fellows are attracted to the field of hemoglobinopathy- sickle cell disease, it established the Fellowship Grant Program in 2011 and the first fellowship grant, valued at $2,000 was awarded to the Red Blood Disorder Clinic at Toronto General Hospital.

This year, SCAGO, in partnership with Vertex Pharmaceuticals Inc, will be awarded a fellowship grant of $25,000 to an institution with an interest in sickle cell disease research.

The Sickle Cell Awareness Group of Ontario will provide the institution with a $25,000 grant towards the salary of a fellow with an interest in conducting research on sickle cell disease.

Nature of Research
Any area of research (including but not limited to innovative treatment and the advancement of care, etc.) will be considered provided the focus remains on sickle cell disease.

Application Process
Institutions interested in applying for this grant are required to send a letter of intent (1000 words maximum) to: researchchair@sicklecellanemiaca.live-website.com copying: research@sicklecellanemiaca.live-website.com. The letter may include the following information:

  • Why you are applying to SCAGO’s Fellowship Grant Program
  • Information on the Fellow who will benefit from the Grant and their research interest
  • Any notable contributions to sickle cell disease made by your institution
  • How your institution intends to promote the Fellowship program should you be awarded the grant

Deadline for application
Applications must be completed and submitted electronically by April 17, 2023 Applications will not be accepted after the deadline date. Incomplete applications will not be considered.

Selection Criteria/Review Process
SCAGO’s research committee, consisting of members with professional backgrounds in sickle cell disease as well as patient advocates, will review the application for scientific merit and appropriateness for funding.